22157.jpg
China Pembrolizumab Market Report 2021: Market Size will Expand in the Future Due to the Increased Numbers of Approved Indications
April 19, 2021 08:18 ET | Research and Markets
Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on the Chinese Pembrolizumab Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering. After Pembrolizumab...
22157.jpg
Global Immuno-Oncology Market Report 2021-2026: Merck's Keytruda (Pembrolizumab) Leads the Market
March 29, 2021 06:53 ET | Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research" report has been added to ResearchAndMarkets.com's...
22157.jpg
United States Cancer Biosimilar Market Report 2021: $15 Billion Opportunity, Drug Dosage, Price & Clinical Trials Insight to 2026
March 19, 2021 06:43 ET | Research and Markets
Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "US Cancer Biosimilar Market Opportunity, Drug Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's...
new logo.jpg
Immutep Enters Second Collaboration With MSD For A New Randomised Phase IIB Trial In Head And Neck Cancer
March 16, 2021 08:00 ET | Immutep Limited
New Phase IIb trial called TACTI-003, to evaluate eftilagimod alpha in combination with MSD’s KEYTRUDA® (pembrolizumab) in 1st line head and neck squamous cell carcinoma (HNSCC)HNSCC is one of the...
new logo.jpg
Immutep Expands Part B of TACTI-002 Study
March 05, 2021 08:00 ET | Immutep Limited
Sydney, AUSTRALIA, March 05, 2021 (GLOBE NEWSWIRE) -- – Immutep Limited (ASX: IMM; NASDAQ: IMMP) a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases,...
22157.jpg
I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market, 2020 Report - Upcoming Product Launches in Adoptive Cell Therapy Segment Hold Future Growth Potential
February 17, 2021 08:38 ET | Research and Markets
Dublin, Feb. 17, 2021 (GLOBE NEWSWIRE) -- The "I-O Therapy Combinations Spurring Growth of the Global Immuno-oncology Market" report has been added to ResearchAndMarkets.com's offering. This...
22157.jpg
Global Checkpoint Inhibitors Market Report 2020-2030: COVID-19 Growth and Changes
December 22, 2020 05:23 ET | Research and Markets
Dublin, Dec. 22, 2020 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. ...
22157.jpg
Immune Checkpoint Inhibitors Market, 2025
October 30, 2020 04:53 ET | Research and Markets
Dublin, Oct. 30, 2020 (GLOBE NEWSWIRE) -- The "Immune Checkpoint Inhibitors Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The...
Vaccinex logo
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
September 17, 2020 08:00 ET | Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a novel approach to treating cancer and neurodegenerative disease...
rhL
Rhizen Pharmaceuticals S.A. Announces Presentations on Tenalisib (RP6530) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 29, 2018 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, May 29, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., a clinical-stage biotechnology company developing Tenalisib (RP6530), a highly selective and orally...